NCT03775265
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 684 versions: 10 with changes below, 40 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion date changed from estimate of Jun 1, 2027 to Jul 23, 2026
- Study completion pushed from Jun 1, 2027 to Nov 13, 2027
- Enrollment target: estimated 475 to confirmed 485
- Notable Eligibility criteria expanded, about 57 words
- Secondary endpoints: details revised at 5 of 8 entries
- Study description revised
- Site details revised at 23 of 365 sites
- Minor Study sites: 366 to 365v680
- Minor Study sites revised (366)v679
- Minor Study sites revised (366)v677
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites revised (366)v676
- Minor Site details revised at 1 of 366 sitesv675
- Minor Study sites revised (366)v674
- Minor Study sites revised (366)v673
- Minor Site details revised at 1 of 366 sitesv672
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin
Procedures: Biopsy of Bladder, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor
Other: Quality-of-Life Assessment, Survey Administration
Radiation: Radiation Therapy
Sites
365 sites in 1 country